Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel shows promise for clearing acne

NCT ID NCT07244887

Symptom relief Sponsor: Oya Helin Dundar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a gel containing dapsone (7.5%) against a placebo gel in 100 adults with mild-to-moderate acne. Participants applied the gel once daily for 8 weeks, and researchers tracked changes in acne lesions, skin oil, redness, and quality of life. The goal was to see if the active gel works better than the placebo at improving acne and related skin issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

100 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 50 years with a clinical diagnosis of mild-to-moderate acne vulgaris. * No systemic or topical acne treatment within the past 1 month (30 days). * Able and willing to provide written informed consent. Exclusion Criteria: * Pregnancy or breastfeeding. * Systemic retinoid or systemic antibiotic use within the past 6 months. * Active dermatologic or systemic disease that could interfere with study participation or outcome assessments. * Known hypersensitivity to dapsone or any component of the study product.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris Erythema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

Contacts and locations

Locations

  • Istanbul Training and Research Hospital

    Istanbul, 34000, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.